Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab Clinical Trials in Lebanon, New Hampshire

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors